Core Viewpoint - Biofrontera Inc. has successfully locked the databases for two clinical studies evaluating Ameluz PDT, marking a significant milestone ahead of expected data and regulatory events in 2026 [1][2][10] Group 1: Clinical Studies and Data - The databases for the Phase 3 clinical study on Ameluz PDT for actinic keratosis (AK) and the Phase 2 study for moderate to severe acne vulgaris were locked on January 5, 2026 [2][10] - Data from these studies will be available in February 2026, enabling statistical analysis and unblinding of results [3][10] - Actinic keratosis and acne vulgaris are the most commonly diagnosed skin disorders in the US, affecting tens of millions of patients [3][10] Group 2: Market Opportunity and Unmet Needs - There is a significant unmet need for effective treatments for AK and acne vulgaris, with current therapies often limited by side effects [4][12] - The U.S. acne treatment market was valued at $5.7 billion in 2024 and is projected to grow at a 5.3% CAGR, highlighting the demand for safer alternatives [12] - The potential for increased use of Ameluz PDT is noted, especially if approved for broader indications beyond the face and scalp [4][5] Group 3: Regulatory Plans - Pending positive outcomes from the Phase 3 AK study, the company plans to submit a supplemental New Drug Application (sNDA) to the FDA in Summer 2026 [5][6] - Results from the Phase 2 acne vulgaris study are expected to be presented to the FDA in early Q3 2026, which will support a future Phase 3 program [5][6] Group 4: Company Overview - Biofrontera Inc. specializes in the treatment of dermatological conditions using photodynamic therapy (PDT) and commercializes Ameluz for treating AK and other skin lesions [13]

Core Insights - Biofrontera Inc. has successfully transferred the New Drug Application (NDA) and Investigational New Drug Application (IND) for Ameluz and the RhodoLED Lamp Series, allowing the company to independently manage clinical development and marketing in the US [1][2] - The transfer includes 11 granted US patents, 10 pending US patent applications, and 19 international patent applications related to the products, enhancing Biofrontera's intellectual property portfolio [1][2] - The completion of these transfers is seen as a significant milestone in Biofrontera's strategy to optimize operations and pursue new clinical indications for its products [3] Company Overview - Biofrontera Inc. is a biopharmaceutical company focused on photodynamic therapy (PDT) for dermatological conditions, particularly Actinic Keratosis and other skin lesions [4] - The company aims to expand the use of its products to treat non-melanoma skin cancers and moderate to severe acne through ongoing clinical trials [4]

Core Insights - Soligenix, Inc. announced positive results from the third cohort of its Phase 2a trial for SGX302, a treatment for mild-to-moderate psoriasis, utilizing an optimized gel formulation of synthetic hypericin [1][2][3] Company Overview - Soligenix is a late-stage biopharmaceutical company focused on developing products for rare diseases with unmet medical needs, including treatments for psoriasis and cutaneous T-cell lymphoma (CTCL) [1][12] Clinical Trial Results - The third cohort of the Phase 2a trial involved four patients treated with an improved gel formulation for 18 weeks, showing no drug-related adverse events and significant improvements in various psoriasis assessment indices [2][5] - One patient achieved an "Almost Clear" status in the Investigator Global Assessment (IGA), with a PASI score improvement exceeding 50%, indicating treatment success [2][3] - The gel formulation was designed for easier application compared to the previous ointment, leading to similar or improved outcomes [2][5] Market Potential - Psoriasis affects approximately 60-125 million people globally, with a treatment market valued at around $15 billion in 2020, projected to reach $40 billion by 2027 [3][10] - The success of HyBryte™ in CTCL trials suggests potential for SGX302 in treating psoriasis, which is also linked to dysregulated T-cells [3][12] Treatment Mechanism - Synthetic hypericin is a first-in-class photodynamic therapy that activates T-cell apoptosis using visible light, avoiding long-term risks associated with traditional UV light therapies [4][7] - This approach aims to treat deeper skin lesions effectively while minimizing risks of secondary malignancies and serious infections associated with systemic treatments [7][9] Psoriasis Overview - Psoriasis is a chronic inflammatory skin condition affecting quality of life and is associated with various comorbidities, including cardiovascular and psychological conditions [8][10] - The most common type, plaque psoriasis, affects about 80% of patients, with varying severity levels impacting treatment approaches [8][9]

Registration No. 333- As filed with the Securities and Exchange Commission on December 5, 2025. UNITED STATES SECURITIES AND EXCHANGE COMMISSION (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 47-3765675 (Primary Standard Industrial Classification Code Number) Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOFRONTERA INC. (I.R.S. Employer Identification No.) 660 Main Street Woburn, M ...

Core Insights - Biofrontera Inc. has completed the final patient visit in its Phase 1 pharmacokinetic study of Ameluz gel for treating mild to moderate actinic keratoses [1][4] - The data from this study, along with results from a recent Phase 3 clinical trial, will support a supplemental New Drug Application to the FDA to expand Ameluz's label [2][4] - Actinic keratoses are common pre-cancerous skin lesions that can progress to squamous cell carcinoma if untreated, affecting approximately 58 million people in the US as of 2020 [5] Company Overview - Biofrontera Inc. specializes in the development and commercialization of photodynamic therapy for dermatological conditions, particularly focusing on the drug-device combination Ameluz and the RhodoLED lamp series [6] - The company aims to extend the use of its products to treat non-melanoma skin cancers and moderate to severe acne [6] Clinical Study Details - The Phase 1 study evaluated the pharmacokinetic profile of 5-aminolevulinic acid and its metabolite protoporphyrin IX during Ameluz-PDT treatment on the upper extremities, neck, or trunk [3][8] - Seventeen patients participated in the study, receiving one PDT treatment with blood samples taken over 10 hours to assess systemic exposure [3] Future Plans - Pending positive outcomes from the Phase 1 and Phase 3 studies, Biofrontera plans to submit a supplemental New Drug Application to the FDA in Summer 2026 [4][8]

Core Viewpoint - Biofrontera Inc. has submitted a supplemental New Drug Application (sNDA) to the FDA for Ameluz-PDT, seeking approval for the treatment of superficial basal cell carcinoma (sBCC) [1][9]. Submission Details - The submission includes comprehensive efficacy data from a Phase 3 study and a one-year follow-up, along with an integrated safety assessment from U.S. and European clinical studies [2]. - The filing aims to expand the Ameluz label to include sBCC treatment using BF-RhodoLED or RhodoLED XL red light lamps [2]. Study Overview - A double-blind, randomized, placebo-controlled Phase 3 study evaluated Ameluz-PDT in 187 patients with confirmed sBCC [3]. - Participants received one or two cycles of PDT treatments, with a second cycle possible at three months if needed [3]. Efficacy Results - The primary endpoint showed a 65.5% clearance rate in the Ameluz-PDT group compared to 4.8% in the placebo group, with a highly significant statistical difference (p<0.0001) [4]. - Key secondary endpoints indicated even higher efficacy: - Complete histological clearance in 75.9% of Ameluz patients vs. 19.0% in placebo [5]. - Complete clinical clearance in 83.4% of Ameluz patients vs. 21.4% in placebo [5]. - Total clearance of all sBCC lesions in 64.1% of Ameluz patients vs. 4.8% in placebo [5]. Patient Outcomes - Patient-reported outcomes showed 85.5% rated their treatment satisfaction and aesthetic outcome with Ameluz-PDT as very good or good [6]. - One-year follow-up data indicated low recurrence rates and excellent long-term cosmetic outcomes [6]. Industry Context - BCC is the most common skin cancer in the U.S., with over 3 million cases diagnosed annually [9]. - Actinic keratosis (AK), a precursor to skin cancer, affects approximately 58 million people in the U.S., with 13 million AK treatments performed in 2020 [8]. Company Perspective - The CEO of Biofrontera expressed optimism about the submission aligning with European study results and the potential market leadership in PDT for cutaneous oncology [7]. - A board-certified dermatologist highlighted the study's findings as reinforcing the value of Ameluz-PDT for treating sBCC [7].

Core Viewpoint - Biofrontera Inc. has successfully completed a restructuring and asset purchase agreement with its former parent company, Biofrontera AG, acquiring full U.S. rights to Ameluz and RhodoLED, which is expected to enhance its financial and operational profile [1][5][8] Group 1: Transaction Details - Biofrontera Inc. has acquired all U.S. assets and rights related to Ameluz and RhodoLED, including the New Drug Application (NDA), Investigational New Drug Application (IND), manufacturing rights, intellectual property, and personnel [1][3] - The transaction includes a new earnout structure where Biofrontera Inc. will pay 12% of U.S. net sales of Ameluz up to $65 million and 15% for sales above that threshold, replacing the previous model of 25%-35% [2][8] - The transaction was funded through an $11 million investment led by Rosalind Advisors and AIGH Capital Management, with Biofrontera AG receiving a 10% post-money equity stake in Biofrontera Inc. [4][8] Group 2: Operational Implications - Following the agreement, Biofrontera Inc. will take full responsibility for the manufacturing, regulatory, quality management, pharmacovigilance, and commercialization of Ameluz and RhodoLED in the U.S. [3] - The company anticipates completing the full transfer of assets and personnel by late Q4 2025 or early Q1 2026 [3] - The new earnout structure is expected to drive significant gross margin expansion starting in Q4 2025, positioning the company for accelerated growth of Ameluz and potential label expansion [5]

Summary of Biofrontera Inc. Conference Call Company Overview - **Company Name**: Biofrontera Inc. (NasdaqCM: BFRI) - **Industry**: Dermatology and Oncology - **Specialization**: Photodynamic therapy (PDT) for treating actinic keratosis (AK) and other dermatologic conditions - **Key Products**: Ameluz and BF-RhodoLED lamps - **Market Position**: Focused on expanding treatment indications and vertical integration in the U.S. pharmaceutical market [2][4] Financial Performance - **2024 Revenue**: $37.3 million - **Year-to-Date Revenue (Q2 2025)**: $17.6 million, up from $15.8 million in Q2 2024 - **Long-term Gross Margin**: Expected to be 80-85%, with current year-to-date gross margin at 71% for Q2 2025, compared to 45% in 2024 [3][17] - **Adjusted EBITDA**: Year-over-year adjusted EBITDA for 2025 is flat due to one-time legal expenses [18] Market Opportunity - **Actinic Keratosis Market**: Estimated market opportunity of $500 million - **Total Addressable Market**: Approximately $4 billion, focusing on a $520 million market suited for field therapy [3][10] - **Reimbursement**: Ameluz priced at $363, with an average reimbursement of $262 per treatment for healthcare professionals [11] Product Efficacy and Technology - **Efficacy**: 91% clearance rate after one to two treatments, significantly better than competitors [9] - **Technology**: Utilizes nanoemulsion technology for better absorption and penetration compared to traditional treatments [10][21] Competitive Landscape - **Competitors**: Main competitor is Levulan, which is limited to spot treatment; Biofrontera is the only PDT drug formulated for field treatment [21][22] - **Advantages**: Superior penetration and efficacy of Ameluz compared to cryotherapy and topical treatments [21] Growth Strategy - **Label Expansion**: Ongoing clinical trials for non-melanoma skin cancers and acne, with expected FDA submissions for basal cell carcinoma and trunk/extremities indications by mid-2027 [16][24] - **Customer Conversion**: Strategy to convert patients from other therapies to Ameluz, optimizing salesforce productivity [14][15] - **Inorganic Growth**: Actively seeking late-stage or commercial products that complement PDT [17] Leadership and Management - **CEO**: Professor Hermann Luebbert, founder of Biofrontera - **Key Executives**: Includes George Jones (Chief Commercial Officer) and Sam Whitcomb (VP of Corporate Strategy) [19] Financial Outlook - **Break-even Expectation**: Anticipated break-even in 2026, with modest growth and new indications contributing to revenue [24] - **Cash Position**: $3.5 million cash on hand, with long-term convertible debt of $4.3 million [19] Additional Insights - **Cyclical Revenue Pattern**: Revenue typically peaks in Q4 and Q1, with a decline in summer months due to patient behavior [25] - **Intellectual Property**: Strong patent protection for nanoemulsion technology until 2028, with an extension for a new formulation until 2043 [12] This summary encapsulates the key points discussed during the Biofrontera Inc. conference call, highlighting the company's market position, financial performance, growth strategies, and competitive advantages.

Core Insights - Biofrontera Inc. has engaged Lytham Partners to enhance its investor relations and shareholder communication strategy, aiming to broaden its investor base and improve market recognition of its value proposition [1][3]. Company Overview - Biofrontera Inc. is a biopharmaceutical company focused on photodynamic therapy (PDT) for dermatological conditions, particularly through its drug-device combination Ameluz® and the RhodoLED® lamp series [4]. - The company is actively conducting clinical trials to expand the application of its products to treat non-melanoma skin cancers and moderate to severe acne [4]. Recent Developments - The company has undertaken significant actions, including restructuring its relationship with its former parent company, acquiring U.S. intellectual property, and securing $11 million in new funding, positioning itself for potential profitability in upcoming quarters [3]. - Biofrontera aims to establish itself as a leading specialty dermatology company in the U.S. by advancing innovative therapies that cater to dermatology professionals and their patients [3]. Strategic Partnership - Lytham Partners, with over 20 years of experience in investor relations, will provide a comprehensive platform for Biofrontera to enhance its visibility among institutional investors and streamline its communication practices [2]. - The partnership is expected to support Biofrontera in keeping shareholders informed about the company's developments and progress [3].

Core Viewpoint - Biofrontera Inc. has completed the active treatment phase of its Phase 3 clinical trial for Ameluz PDT, targeting mild to moderate actinic keratoses, with all 172 patients now entering a 12-month follow-up phase expected to conclude in Q2 2026 [1][4]. Group 1: Clinical Trial Details - The Phase 3 study is a multicenter, randomized, double-blind trial assessing the safety and efficacy of Ameluz PDT compared to a vehicle gel for treating actinic keratoses on the extremities, neck, and trunk [3]. - Patients received one to three tubes of either Ameluz or vehicle gel applied to areas of approximately 80, 160, or 240 cm², with a single PDT treatment and a possible second treatment at 12 weeks if needed [3]. - The study enrolled a total of 172 subjects, who will be monitored for 12 months to evaluate recurrence and new lesion development [3][7]. Group 2: Market and Strategic Implications - The completion of this trial phase is seen as a significant milestone for Biofrontera, enhancing the market potential for Ameluz following recent FDA approval for using up to three tubes per treatment [4]. - The company plans to submit a supplemental New Drug Application (sNDA) to the FDA in Q2 2026, contingent on positive trial outcomes [4][7]. - Expanding treatment options for actinic keratoses beyond the face and scalp addresses a critical unmet need in dermatology, as 58 million US adults are affected by this condition [2][5]. Group 3: Company Overview - Biofrontera Inc. specializes in the treatment of dermatological conditions, focusing on photodynamic therapy (PDT) and commercializing the drug-device combination Ameluz with the RhodoLED lamp series [6]. - The company is actively conducting clinical trials to extend the use of its products for treating non-melanoma skin cancers and moderate to severe acne [6].